See more : New City Development Group Limited (0456.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Prelude Therapeutics Incorporated (PRLD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Prelude Therapeutics Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
- Sam Industries Limited (SAMINDUS.BO) Income Statement Analysis – Financial Results
- Harbin Gloria Pharmaceuticals Co., Ltd (002437.SZ) Income Statement Analysis – Financial Results
- Varia US Properties AG (0RKW.L) Income Statement Analysis – Financial Results
- PT Sawit Sumbermas Sarana Tbk. (SSMS.JK) Income Statement Analysis – Financial Results
- Fountaine Pajot Société anonyme (ALFPC.PA) Income Statement Analysis – Financial Results
Prelude Therapeutics Incorporated (PRLD)
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.17M | 3.04M | 2.24M | 542.00K | 382.00K | 149.00K |
| Gross Profit | -1.17M | -3.04M | -2.24M | -542.00K | -382.00K | -149.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 103.39M | 92.89M | 86.78M | 48.18M | 24.28M | 12.62M |
| General & Administrative | 28.88M | 30.65M | 26.96M | 10.59M | 3.83M | 2.35M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.88M | 30.65M | 26.96M | 10.59M | 3.83M | 2.35M |
| Other Expenses | 0.00 | 8.10M | 2.04M | 1.83M | 539.00K | 295.00K |
| Operating Expenses | 132.28M | 123.54M | 113.74M | 58.76M | 28.11M | 14.98M |
| Cost & Expenses | 132.28M | 123.54M | 113.74M | 58.76M | 28.11M | 14.98M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.17M | 3.04M | 2.24M | 542.00K | 382.00K | 149.00K |
| EBITDA | -131.11M | -122.22M | -112.82M | -58.22M | -27.73M | -14.83M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -132.28M | -123.54M | -113.74M | -58.76M | -28.11M | -14.98M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.45M | 8.10M | 2.04M | 1.83M | 539.00K | 295.00K |
| Income Before Tax | -121.83M | -115.44M | -111.69M | -56.93M | -27.57M | -14.68M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -8.10M | -915.00K | 335.70K | 210.14K | 295.00K |
| Net Income | -121.83M | -107.34M | -110.78M | -56.93M | -27.57M | -14.68M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.02 | -2.27 | -2.33 | -1.30 | -0.85 | -0.46 |
| EPS Diluted | -2.02 | -2.27 | -2.33 | -1.30 | -0.85 | -0.46 |
| Weighted Avg Shares Out | 60.36M | 47.37M | 47.60M | 43.71M | 32.40M | 32.11M |
| Weighted Avg Shares Out (Dil) | 60.36M | 47.37M | 47.60M | 43.71M | 32.40M | 32.11M |
Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference
Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
The 10 Most Shorted Stocks Right Now for Friday, Dec. 17
Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update
Why BofA Is Turning Bullish On Prelude Therapeutics
Prelude Therapeutics (PRLD) Enters Oversold Territory
Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences
Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Source: https://incomestatements.info
Category: Stock Reports